GlassScriptPhysician profile
Benjamin M Wilson
NPI 1417247644
$2,595.10
in general payments reported to CMS, 2019-2025
28 companies · $620 in 2025
The $620 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.52 · 2020: $58.79 · 2021: $224 · 2022: $464 · 2023: $608 · 2024: $563 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,791.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $417.05 | 2021-2025 | Vraylar, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $396.92 | 2022-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $302.43 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $170.82 | 2021-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $158.71 | 2020-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $156.25 | 2022-2024 | Breztri, Farxiga |
| Novo Nordisk INC | $148.66 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $89.68 | 2021-2025 | Repatha |
| Axsome Therapeutics, INC. | $85.36 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $81.48 | 2025 | Fanapt |
| Indivior INC. | $71.26 | 2022 | |
| Eisai INC. | $61.23 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.37 | 2024-2025 | |
| Lundbeck LLC | $57.46 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $56.29 | 2024 | Verquvo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $39.46 | 2025 | Iovera |
| Pfizer INC. | $33.45 | 2023 | |
| Janssen Pharmaceuticals, INC | $33.05 | 2022-2023 | Spravato |
| Alkermes, INC. | $28.93 | 2023 | Aristada, Lybalvi |
| Astellas Pharma US INC | $23.87 | 2025 | Veozah |
| Neurelis, INC. | $19.71 | 2025 | Valtoco |
| Insulet Corporation | $18.83 | 2024 | Omnipod |
| Vertex Pharmaceuticals Incorporated | $17.20 | 2025 | |
| Sunovion Pharmaceuticals INC. | $15.84 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.59 | 2022 | |
| Melinta Therapeutics, LLC | $13.84 | 2019 | |
| Nestle Healthcare Nutrition INC. | $12.55 | 2020 | |
| Allergan, INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.